Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Thelper
Oslo, Norway
A
1-10 Employees
2019
Key takeaway
Thelper AS is developing innovative immunotherapies targeting viral antigens expressed in tumors but absent in healthy tissue, which could lead to reduced toxicity for patients. Their focus on transforming treatment for solid tumors aligns with advancements in cancer therapies.
Reference
Core business
Thelper AS
NEC OncoImmunity AS
Oslo, Norway
A
11-50 Employees
2014
Key takeaway
NEC OncoImmunity AS specializes in artificial intelligence-driven solutions that enhance the prediction of immunogenic antigens, which is crucial for the development of personalized cancer immunotherapies like CAR-T cell therapy. Their innovative software focuses on discovering neoantigen-based treatments, positioning the company at the forefront of advancements in cancer immunotherapy.
Reference
Core business
NEC OncoImmunity AS
EXACT THERAPEUTICS AS
Oslo, Norway
A
1-10 Employees
2012
Key takeaway
EXACT Therapeutics AS is developing Acoustic Cluster Therapy (ACT®), a novel ultrasound-mediated technology that enhances the delivery of therapeutic agents, including those used in cancer treatment. This innovative approach aims to improve the effectiveness of immunotherapy and other oncological treatments through precise and targeted delivery.
Reference
Core business
Company — EXACT THERAPEUTICS
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Bioinvent International AB
Rana, Norway
A
1-10 Employees
2018
Key takeaway
BioInvent is a clinical-stage company focused on developing antibody-based immunotherapies for cancer, particularly targeting hematological cancers and solid tumors. With a strong pipeline and expertise in immunology and cancer biology, BioInvent is well-positioned to contribute to the expanding market for innovative cancer therapies.
Reference
Core business
About Us | BioInvent
ClexBio
Oslo, Norway
A
1-10 Employees
2020
Key takeaway
ClexBio is a pre-clinical stage regenerative medicine company focused on innovative tissue engineering solutions. Their proprietary technology platform enables scalable tissue generation, which may have implications for advancements in therapies like CAR-T cell therapy.
Reference
Core business
ClexBio | Engineering Human Tissue Transplants
ClexBio is a biotech company creating innovative solutions for tissue engineering and single-cell techniques using advanced microfluidics and the proprietary CLEX hydrogel technology.
Nordic Nanovector
Oslo, Norway
A
11-50 Employees
2009
Key takeaway
Thor Medical is focused on developing innovative therapies, including promising radionuclide therapy for cancer treatment.
Reference
Core business
Our company | Nordicnanovector
Nordic Nanovector is committed to develop, manufacture and deliver innovative therapies to patients in an effort to address major unmet medical needs and advance cancer care.
OncoloMed AS
Stavanger, Norway
A
1-10 Employees
2011
Key takeaway
OncoloMed emphasizes its commitment to providing innovative cancer treatments and personalized care, ensuring that patients have access to the best options available. This approach aligns with the desire for effective treatment choices in the fight against cancer.
Reference
Core business
Personalised Cancer Treatment | Virtual Cancer Centre - OncoloMed
OncoloMed believe a cancer suffering family should have the right to the right treatment choices. Learn more about our personalised cancer treatment services that help empower you in your cancer journey.
BerGenBio
Bergen, Norway
A
11-50 Employees
2007
Key takeaway
BerGenBio is a clinical-stage biopharmaceutical company focused on developing innovative drugs for aggressive diseases, including cancer. They are working on selective AXL inhibitors, which may have implications for cancer treatment.
Reference
Core business
Partnering - BerGenBio
Palion Medical
Trondheim, Norway
A
11-50 Employees
2018
Key takeaway
The company is developing a novel neurostimulation system that targets occipital nerves to reduce the pain and frequency of severe headache attacks. Their innovative approach involves precise delivery of electrical currents, which may be relevant for advancements in pain management therapies.
Reference
Core business
Man & Science
Diatec Monoclonals AS
Oslo, Norway
A
51-100 Employees
1988
Key takeaway
Curida Diatec is a biotechnology company with over 25 years of experience in antibody production and conjugation. Their expertise in custom production may be relevant for advancements related to CAR-T cell therapy.
Reference
Core business
Front page - Curida Diatec
Curida Diatec is a Norwegian founded biotechnology company with more than 25 years experience in antibody production and conjugation. We take pride in communicating with our customers along the production process to secure a best possible finished product for your needs. Your expert and reliable partner in: Custom production of monoclonal antibodies, small and large scale […]
Technologies which have been searched by others and may be interesting for you:
In Norway, those interested in the CAR-T cell therapy industry should consider several critical factors. Regulatory frameworks are paramount, as the Norwegian Medicines Agency oversees the approval and monitoring of advanced therapies, ensuring compliance with both national and EU regulations. The industry is also influenced by the country's strong emphasis on research and development, providing opportunities for collaboration with leading universities and research institutions. Challenges include the high costs associated with CAR-T therapies, which can limit accessibility and market growth. The competitive landscape features a mix of established pharmaceutical companies and innovative biotech startups, increasing the need for differentiation and strategic partnerships. Environmental concerns are increasingly relevant, particularly around the manufacturing processes and waste management associated with cell therapy production. Moreover, Norway's commitment to healthcare innovation and sustainability can create a favorable environment for CAR-T therapies, aligning with global trends towards personalized medicine. Understanding these dynamics is essential for anyone researching companies in this field, as they shape the opportunities and challenges that will influence the industry's future trajectory in Norway.
Some interesting numbers and facts about your company results for CAR-T Cell Therapy
| Country with most fitting companies | Norway |
| Amount of fitting manufacturers | 36 |
| Amount of suitable service providers | 15 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1988 |
| Youngest suiting company | 2020 |
Some interesting questions that has been asked about the results you have just received for CAR-T Cell Therapy
What are related technologies to CAR-T Cell Therapy?
Based on our calculations related technologies to CAR-T Cell Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on CAR-T Cell Therapy?
The most represented industries which are working in CAR-T Cell Therapy are Other, Biotechnology, IT, Software and Services, Medical, Finance and Insurance
How does ensun find these CAR-T Cell Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.